Patients with AIDS often experience recurrent infections with varicella-zoster virus (VZV) requiring repeated or prolonged treatment with acyclovir (ACV), which may lead to the development of ACV resistance. The ACV resistance of isolates recovered from such patients is associated with diminished VZV thymidine kinase (TK) function. We determined the nucleotide sequences of the TK genes of 12 ACV-resistant VZV strains purified from nine patients with AIDS. Five VZV strains contained nucleotide deletions in their TK genes, introducing a premature termination codon which is expected to result in the production of a truncated protein. No detectable full-length TK protein could be immunoprecipitated from extracts of cells infected with these virus strains. These TK-deficient strains were cross resistant to the TK-dependent antiviral agents ACV, 9-(4-hydroxy-3-hydroxymethylbutyl-yl)guanine (penciclovir), and 1-1-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BVaraU). The remaining seven strains each contained a nucleotide change that resulted in an amino acid substitution in the TK protein. These substitutions occurred throughout the TK protein, namely, in the ATP-binding site, the nucleoside-binding site, between the two binding sites, and at the carboxy terminus of the protein. We determined the effects of these mutations on the stability of TK protein expression in virus-infected cells and on the sensitivity of mutants to the TK-dependent antiviral agents ACV, BVaraU, and penciclovir.
Varicella-zoster virus (VZV), a member of the herpesvirus family, encodes a 35-kDa thymidine kinase (TK) protein that possesses both thymidine-and thymidylate-phosphorylating activities (20, 34, 51) . The VZV TK protein has approximately 28% overall amino acid sequence homology with the herpes simplex virus (HSV) TK protein; however, two noncontiguous regions that are proposed to be involved in nucleotide (ATP) and nucleoside (substrate) binding show 55 and 64% homology, respectively (27, 49) . Single-amino-acid substitutions in either of these conserved sites alter the enzymatic activity of both the HSV and the VZV TK proteins (10, 29, 30, 33, 49) and confer resistance to TKdependent antiviral agents such as acyclovir (ACV) and 1-,-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BVaraU; brovavir; Sorivudine). VZV inhibition by these antiviral agents is due to the competitive inhibition of the viral DNA polymerase by nucleoside triphosphates. For ACV triphosphate, HSV inhibition has been shown to result from both DNA chain termination and enzyme inactivation (14, 42) . ACV is selectively phosphorylated by the viral TK protein to its monophosphate derivative, which is then converted by host cellular kinases to the triphosphate form. By contrast, BVaraU is phosphorylated to the diphosphate form by the viral thymidine and thymidylate kinase activities (54) . The triphosphate forms of these antiviral agents act as preferred substrates for the viral DNA polymerase and disrupt viral DNA synthesis (12, 18, 19, 36, 45, 50) .
ACV is an effective treatment for mucocutaneous HSV infections (38, 53, 55) and has shown efficacy in the treatment of primary and recurrent VZV infections. Immunocompromised patients, especially those with AIDS, often experience recurrent infections with VZV that require prolonged treatment with ACV. A lack of clinical response has * Corresponding author.
been correlated with the presence of ACV-resistant VZV in several patients with AIDS (25, 41, 47) . Most of the ACVresistant VZV isolates recovered from these patients contained either TK-deficient or TK-altered virus, although there were two documented cases in which VZV with a DNA polymerase-altered phenotype was associated with ACV resistance (41, 47) .
The molecular basis of ACV resistance in VZV has been studied primarily with laboratory-derived resistant mutants. This study represents the first comprehensive analysis of the mutations in VZV associated with clinical ACV resistance. In this study, we sequenced the TK genes from 12 virus strains purified from isolates of nine AIDS patients whose VZV infections had shown poor clinical responses to chronic ACV therapy. VZV isolated from the lesions of these nine patients was resistant to ACV in vitro but was sensitive to the polymerase-dependent drugs foscarnet (PFA) and vidarabine (araA) (24, 32, 46) . This finding is consistent with the presence of a TK mutation. We determined the nucleotide sequence changes in the TK gene associated with ACV resistance and the effect of these mutations on the level of TK protein produced during virus infection. Finally, the sensitivities of these virus strains to other TK-dependent antiviral agents were determined.
MATERIALS AND METHODS
Virus and cell strains. Clinical VZV isolates were obtained from cutaneous lesions of patients who failed to respond to ACV treatment. The detailed clinical histories and ACV therapies of five of these patients, corresponding to isolates 8807, 8808, 8811, 8812, and 9012, have been described previously (25, 47) . Each isolate was assigned a number based on the year it was isolated (first 2 digits) and its order of arrival in the laboratory in that year (last 2 digits). Drug sensitivity phenotypes were determined for these mixed populations, and the viral TK activities were assessed by (6, 9, 17, 47, 50) . Therefore, to obtain a preliminary determination of the nature of ACV resistance in the unpurified VZV isolates, 50% effective doses (ED50s) were determined for the TKdependent antiviral agent ACV and the polymerase-dependent antiviral agents PFA ( In the case of isolate 9007, the final virus strain, designated 9007-1, which was genetically purified from the mixed isolate, did not reflect the TK phenotype of the original population in the immunoprecipitation analysis of the infected cell extracts ( Fig. 1 and 4 ). This result provided another indication of the genetic heterogeneity that can exist in the clinical isolates.
TK sequence analysis. The TK gene of VZV (Fig. 3) strains were sequenced, and homology greater than 99% was observed between the strains. A comparison of the TK gene sequences of these virus strains to that of the prototype Dumas strain in GenBank showed that each of the isolates had a substitution of S-288 with L that is found in all VZV strains, other than Dumas, examined to date (29, 49) .
The TK genes of 5 of the 12 VZV strains contained either a single-nucleotide deletion (8811-4 and 8811-13), a 2-nucleotide deletion (8807-3 and 9012-4), or a 4-nucleotide deletion (9007-1) ( Table 2 ). The nucleotide deletions found in 8807-3 and 9012-4 were identical, even though the strains originated from different patients. Each of these deletions resulted in a frameshift mutation in the TK gene that introduces a premature termination codon. This should result in the expression of a truncated TK protein.
The remaining seven clinical strains purified from five isolates contained nucleotide substitutions in the TK gene that would result in amino acid substitutions ( infected with these strains showed no evidence of a TK protein.
The introduction of amino acid substitutions had a range of effects on intracellular TK stability. Strains 8808-4, 8812-1, 8812-5, 8812-10, and 8919-1 contained amino acid substitutions present in the nucleoside-binding site of the TK enzyme. Strains 8812-1 and 8812-10, which had identical amino acid substitutions (R-143 to G), led to the production of TK protein that seemed to be expressed at levels somewhat less than those of the wild type. Strain 8812-5, which was isolated from the same patient as strains 8812-1 and 8812-10 but had an amino acid substitution present in the nucleoside-binding site different from those of those two strains, produced essentially wild-type levels of TK protein. Strain 8919-1, which, like 8812-1 and 8812-10, had an amino acid substitution at R-143 (R to K), expressed TK protein at a level that was also equivalent to that of the wild type. Strain 8808-4, which contained substitutions in the nucleoside-binding site at C-138 and in the C terminus of the protein at S-242, appeared to lead to the production of a less stable TK protein, as little TK was immunoprecipitated.
Strain 8901-1, with a predicted ATP-binding site substitution (K-25 to R), expressed a TK protein that appeared to be produced at wild-type levels. Immunoprecipitation of cells infected with 9006-1, which contains an amino acid substitution between the two proposed binding sites (E-59 to G), identified a TK protein that also appeared to be expressed at the same level as that of the wild type.
Therefore, in general, amino acid substitutions in VZV TK proteins that arose in patients during ACV treatment appeared to functionally inactivate the enzyme without substantially altering the intracellular stability of the protein. In contrast, deletions in the nucleotide sequence that are predicted to induce a translational frameshift resulted in a reduction in the stable levels of TK protein expressed in infected cells. (35) that is currently in clinical trials in the United States for VZV infections (Bristol-Myers Squibb), and penciclovir has shown selective activities against HSV-1 and -2 and VZV in vitro (2, 3) . Famciclovir, the oral prodrug of penciclovir, is also in clinical trials (SmithKline Beecham Pharmaceuticals). The activity of each compound is dependent on conversion to the monophosphate derivative by the VZV TK protein.
The in vitro susceptibilities of the VZV strains to ACV, BVaraU, and penciclovir were compared with those of the wild-type virus, Ellen, by a DNA hybridization assay (DNA Hybriwix method) ( Table 3 ). Strain 8807-3, which was predicted to express a truncated TK protein of 231 amino acids, which does not appear to be very stable, was cross resistant to ACV, penciclovir, and BVaraU. Strains 8812-1 and 8812-5, with different amino acid substitutions present in the nucleoside-binding site of the TK protein, were clearly resistant to ACV and penciclovir. These strains, however, showed differential sensitivities to BVaraU, with 8812-1 being 75-fold (ED50 = 0.45 ,uM) and 8812-5 being 3,350-fold (ED5O = 20 ,uM) more resistant to BVaraU than the control strain, Ellen (ED50 = 0.006 ,uM). This degree of in vitro susceptibility may reflect the reduced levels of TK polypeptide detected in virus-infected cells (Fig. 3) . Strain 8919-1, which, like strain 8812-1, has an amino acid substitution at residue 143 (R to K), was resistant to ACV but was sensitive to BVaraU and penciclovir. The conservative amino acid substitution (R-143 to K) in the TK protein of strain 8919-1 did not appreciably affect the sensitivities of the virus to BVaraU (ED5O = 0.02 ,uM) and penciclovir (ED50 = 14 ,uM), whereas the nonconservative substitution (R-143 to G) in the TK protein of strain 8812-1 somewhat shifted the sensitivity of the virus to BVaraU (ED5O = 0.45 ,uM) and severely shifted its sensitivity to penciclovir (ED5O > 150 ,uM).
The nucleotide-binding site mutant, 8901-1, was resistant to all three antiviral agents. This strain was unusual because it produced wild-type levels of TK protein and still phosphorylated deoxy-TdR, although with reduced efficiency, yet it was highly resistant to all three TK-dependent antiviral agents. Strain 9006-1, which contained the mutation between the two binding sites, was resistant to ACV and penciclovir but remained sensitive to BVaraU (ED50 = 0.006 ,uM).
DISCUSSION
The TK genes of 12 clinical VZV strains that were resistant to ACV in vitro were examined by nucleotide sequence analysis and protein expression with virus-infected cells. In both HSV and VZV, antiviral resistance can be due to either a lesion in the TK gene (28, 29, 39, 49) or, less frequently, to an alteration in the polymerase gene (7, 46) . All 12 strains examined in this study contained mutations in their TK genes, which should account for the ACV resistance observed in vitro. These (27) and Robertson and Whalley (44) . tions 681 to 682), even though they originated from different patients.
Seven of the 12 strains had single-nucleotide substitutions in their TK genes, which would result in amino acid substitutions. Five of these strains contained predicted substitutions located in the proposed nucleoside-binding site of the enzyme, whereas only one strain had a substitution in the ATP-binding site. Of the two conserved regions of the HSV TK enzyme, it has been previously shown that mutations in the nucleoside-binding site were more frequently observed in response to selective pressure of antiviral substrates (10, 40 (29, 31, 49) . The R-143 that is substituted in 8812-1, 8812-10 and 8919-1 is conserved among members of the herpesvirus family (Fig. 5) IdC into its DNA. The susceptibility data obtained for the 8808-4 strain were consistent with the production of an unstable enzyme, since the virus was highly resistant to all three of the TK-dependent antiviral agents. Because the protein was apparently unstable, it is unclear what effect the substitution of C-138 with R in the nucleoside-binding site has on the affinity of the TK protein for the antiviral agents.
The nucleoside-binding site (residues 12 to 29) of the VZV TK protein is conserved among other members of the herpesvirus family (Fig. 5) and has a consensus sequence of XXGXXGXGKTXX (33) . The arginine substitution of the conserved lysine at amino acid position 25 in 8901-1 allowed the synthesis of a full-length TK-altered enzyme that conferred cross-resistance of the virus to the TK-dependent antiviral agents tested in this study. The lysine residue is important for the function of several ATP-utilizing proteins, such as p60rc, p37mo, and p1306'"Pi (22, 26, 56) . It was previously proposed that the positive charge of the lysine side chain was required to neutralize the negative charge of the phosphoryl group; however, Kamps and Sefton (26) reported that the substitution of lysine with arginine or histidine did not restore the enzymatic function of the enzyme. In this study, we found that the predicted substitution of K-25 with R allowed the TK enzyme to utilize thymidine, although the relative intensity of incorporated [14C]TdR suggested less efficient deoxy-TdR phosphorylation by this enzyme than by the wild-type VZV TK enzyme (Table 3 ). Kinetic studies with purified viral enzymes should address these apparent differences.
An amino acid substitution (E-59 to G) located between the two binding sites which was present in 9006-1 allowed the expression of a stable, full-length, TK-altered protein.
The E-59 amino acid is not well conserved among the TK proteins of the herpesviruses (Fig. 5) . This substitution resulted in resistance to ACV and penciclovir, both purine nucleoside analogs, without affecting sensitivity to the pyrimidine antiviral agent BVaraU. It also did not affect thymidine incorporation (Table 3 ).
In summary, the ACV resistance found in clinical VZV strains examined in this study was (10) proposed that the ATP-and nucleoside-binding sites and C-336 located in the C terminus of the HSV TK enzyme formed the active center of the HSV TK enzyme. Our data confirm that the ATP-and nucleosidebinding sites are important for the normal function of the TK enzyme; no substitutions were found in the corresponding C terminus cysteine. The phosphorylation of ACV to its monophosphate form initially depends on the binding of the ACV to the TK enzyme. Further enzymological studies of the ACV-resistant mutants will be necessary to determine the affinity of the enzyme for ACV and the rate of phosphorylation of ACV by the TK enzyme. Roberts et al. (43) observed that the TK enzyme of 7-1-3, an ACV-resistant VZV mutant that contains a substitution of R-130 with Q in the conserved region of the nucleoside-binding site of the TK protein (49) , bound ACV more efficiently than did wild-type virus but phosphorylated the antiviral agent at a much slower rate than did wild-type TK enzyme. Enzymatic studies with these ACVresistant mutants should be able to distinguish between the mutations that affect substrate binding and those that affect the phosphorylation rate of the enzyme.
From the original, non-plaque-purified patient isolates, we found that 38% of the clinical ACV-resistant VZV isolates expressed full-length TK protein, a relatively high percentage compared with the 10% of ACV-resistant HSV isolates from 10 patients that expressed a full-length TK polypeptide in a previous study (4) . Interestingly, the one TK variant which induced the synthesis of a full-length HSV TK polypeptide was unable to induce the intracellular phosphorylation of thymidine (4) . In this VZV study, four of six purified strains which synthesized full-length polypeptide were also capable of phosphorylating thymidine. Studies to date indicate that most clinical ACV resistance found in HSV-1 and -2 results from mutations in the viral TK gene, although alterations of the HSV polymerase have been documented previously (4, 7, 46) . The role of the VZV TK protein in the pathogenesis of virus infection has not been studied, because suitable animal models for VZV infection do not exist. A variety of animal models of HSV infection have been utilized to demonstrate the importance of the viral TK protein for virulence and its requirement for reactivation from the latent state (13) . The relatively high percentage of VZV isolates that expressed a full-length functional TK protein may suggest that the TK protein plays an important role in the growth of VZV in vivo. This will be difficult to assess until an appropriate VZV animal model becomes available.
As the number of patients with AIDS increases, there is likely to be a corresponding increase in the number of VZV isolates resistant to ACV and the polymerase inhibitors PFA and araA. Many patients who failed to respond to ACV treatment have subsequently responded to PFA therapy (4, 5, 47, 48) . The resistance of VZV to one TK-dependent antiviral agent may not preclude the use of other TKdependent antiviral agents for management of VZV infections. In this study, some of the strains that were resistant to ACV were not cross resistant to BVaraU or, in one instance, to either BVaraU or penciclovir. Furthermore, patient isolates may contain a mixture of TK variants, as was observed in the patient 8812 isolate, from which two strains that contained different mutations in the nucleoside-binding site of the TK protein were purified. As another example of this heterogeneity, the original 9007 isolate produced a fulllength TK protein that was expressed at wild-type levels, while the one strain plaque purified from the isolate mixture did not express any detectable TK protein in infected cells. Screening of the ACV-resistant isolates against a range of antiviral agents may be important for the successful management of patients who do not respond to polymerase-dependent antiviral agents.
